Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases

Collaboration Overview:
BioAge Labs and Novartis have entered a multi-year research collaboration to discover novel therapeutic targets for age-related diseases by combining BioAge's human longevity datasets with Novartis's expertise in exercise biology45.

Financial Terms:
The deal includes up to $20 million in upfront payments and research funding, with potential future milestones of up to $530 million45.

Research Focus:
The collaboration aims to identify and validate multiple novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate the beneficial effects of physical exercise4.

Platform Utilization:
BioAge's proprietary discovery platform, based on extensive longitudinal human longevity data, will be leveraged to identify determinants of healthy lifespan and provide insights for therapeutic discovery and development4.

Expertise Combination:
The partnership combines BioAge's human longevity data with Novartis's scientific expertise in the biology of physical exercise to discover novel therapeutic targets45.

Potential Impact:
The collaboration underscores the growing recognition that unraveling the biology of aging is a powerful approach to treating disease and aims to bring forward novel treatment options for diseases related to aging4.

Sources:

4. https://ir.bioagelabs.com/news-releases/news-release-details/bioage-labs-announces-multi-year-collaboration-novartis-discover

5. https://www.stocktitan.net/news/BIOA/bio-age-labs-announces-multi-year-collaboration-with-novartis-to-x5rl3lcgvejm.html